STILL’S DISEASE TREATMENT MARKET ANALYSIS

Still’s Disease Treatment MarketSize and Trends

The global Still’s disease treatment market is estimated to be valued at US$ 1.83 Billion in 2023 and is expected to exhibit a CAGR of 4.8% during the forecast period (2023-2030).

Figure 1. Global Still’s Disease Treatment Market Share (%), By Treatment, 2023

Figure 2. Global Still’s Disease Treatment Market Value (US$ Billion), By Region, 2023

Global Still’s Disease Treatment Market - Impact of Coronavirus (COVID-19) Pandemic

Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe, and the World Health Organization (WHO) declared it a public health emergency on January 30, 2020.

COVID-19 affected the economy in three main ways: by directly affecting the production and demand of drugs, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to nationwide lockdowns, several countries, such as China, India, Saudi Arabia, the U.A.E., Egypt, and others, faced problems regarding the transportation of drugs from one place to another.

For instance, according to an article published by National Center for Biotechnology Information, on March 26, 2021, Adult-onset Still's Disease (AOSD) and COVID-19 share several similar clinical and laboratory features, including systemic inflammation, unremitting fever, high serum ferritin, and a potentially life-threatening cytokine release syndrome. Data obtained from single-cell analysis revealed IL-1β-associated inflammasome signatures and a significant expansion of CD14-positive, IL-1β-positive monocytes in the peripheral blood of patients with severe COVID-19. Thus, AOSD and the severe immune over-reaction which occurs in some patients with COVID-19 might be triggered by the same mechanisms.